Medication Nonadherence, “Professional Subjects,” and Apparent Placebo Responders: Overlapping Challenges for Medications Development
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Nonadherence is a major problem in clinical trials of new medications. To evaluate the extent of nonadherence, this study evaluated pharmacokinetic sampling from 1765 subjects receiving active therapy across 8 psychiatric trials conducted between 2001 and 2011. With nonadherence defined as greater than 50% of plasma samples below the limit of quantification for study drug, the percentage of nonadherent subjects ranged from 12.8% to 39.2%. There was a trend toward increased nonadherence in studies with greater numbers of subjects, but an association with nonadherence was not apparent for other study design parameters or subject characteristics. For 2 trials with multiple recruitment sites in geographical proximity, several subjects attempted to simultaneously enroll at separate site locations. The construct of "professional subjects," those who enroll in trials only for financial gain, is gaining attention, and we therefore modeled the impact of professional subjects on medication efficacy trials. The results indicate that enrollment of professional subjects who are destined to succeed (those who will appear to achieve treatment success regardless of study drug assignment) can substantially increase both the apparent placebo response rate and the sample size requirement for statistical power, while decreasing the observed effect size. The overlapping nature of nonadherence, professional subjects, and placebo response suggests that these issues should be considered and addressed together. Following this approach, we describe a novel clinical trial design to minimize the adverse effects of professional subjects on trial outcomes and discuss methods to monitor adherence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Breiman, L. (2001) · Machine Learning · doi:10.1023/a:1010933404324 · Cited by 133,538
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 1×
“D eveloping new medications is a risky and expensive undertaking, with average costs estimated to exceed $1 billion for each new molecular entity (NME) that receives regulatory approval.(1,2) Costs are even higher for central nervous system (CNS) medications, which take longer to develop and often fail after large and…”
BackgroundDiMatteo, M. R. (2004) · Medical Care · doi:10.1097/01.mlr.0000114908.90348.f9 · Cited by 2,169
Placebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002) · JAMA · doi:10.1001/jama.287.14.1840 · Cited by 1,109
Financial Incentive–Based Approaches for Weight Loss: A Randomized Trial
Volpp, K. G., John, L. K., Troxel, A. B., Norton, L., Fassbender, J., & Loewenstein, G. (2008) · JAMA · doi:10.1001/jama.2008.804 · Cited by 923
Farmer, K. C. (1999) · Clinical Therapeutics · doi:10.1016/s0149-2918(99)80026-5 · Cited by 889
A Randomized, Controlled Trial of Financial Incentives for Smoking Cessation
Volpp, K. G., Troxel, A. B., Pauly, M. V., Glick, H. A., Puig, A., Asch, D. A., Galvin, R., Zhu, J., Wan, F., DeGuzman, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmsa0806819 · Cited by 836
Garber, M. C., Nau, D. P., Erickson, S. R., Aikens, J. E., & Lawrence, J. B. (2004) · Medical Care · doi:10.1097/01.mlr.0000129496.05898.02 · Cited by 519
Fava, M., Evins, A. E., Dorer, D. J., & Schoenfeld, D. A. (2003) · Psychotherapy and Psychosomatics · doi:10.1159/000069738 · Cited by 452
Cited by
Mitigating the Effects of Nonadherence in Clinical Trials
Shiovitz, T. M., Bain, E. E., McCann, D. J., Skolnick, P., Laughren, T., Hanina, A., & Burch, D. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.689 · Cited by 114
Self-citationDigitally Enabled, Patient‐Centric Clinical Trials: Shifting the Drug Development Paradigm
Dockendorf, M. F., Hansen, B. J., Bateman, K. P., Moyer, M., Shah, J. K., & Shipley, L. A. (2021) · Clinical and Translational Science · doi:10.1111/cts.12910 · Cited by 67
“21 2.”
Mofsen, A. M., Rodebaugh, T. L., Nicol, G. E., Depp, C. A., Miller, J. P., & Lenze, E. J. (2019) · JMIR Mental Health · doi:10.2196/11845 · Cited by 51
Understanding fraudulence in online qualitative studies: From the researcher's perspective
Panicker, A., Nurain, N., Ibrahim, Z., Wang, C.-H. (., Ha, S. W., Wu, Y., Connelly, K., Siek, K. A., & Chung, C.-F. (2024) · Proceedings of the CHI Conference on Human Factors in Computing Systems · doi:10.1145/3613904.3642732 · Cited by 31
“In some instances, participants may meet inclusion criteria, but they may enroll in the same study multiple times at diferent sites, commonly referred to as "professional subjects" in medical communities, which has been shown to adversely impact study outcomes [45, 66].”
Background
Metadata
- Authors
- McCann, D. J., Petry, N. M., Bresell, A., Isacsson, E., Wilson, E., & Alexander, R. C.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2015-10
- Volume
- 35
- Issue
- 5
- Pages
- 566-573
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2439951792
- Cited by
- 60
- References
- 13
- FWCI
- 6.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Medication Nonadherence, “Professional Subjects,” and Apparent Placebo Responders: Overlapping Challenges for Medications Development. https://app.cochat.ai/papers/10.1097/jcp.0000000000000372
- The paper
- McCann, D. J., Petry, N. M., Bresell, A., Isacsson, E., Wilson, E., & Alexander, R. C. (2015). Medication Nonadherence, “Professional Subjects,” and Apparent Placebo Responders: Overlapping Challenges for Medications Development. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0000000000000372
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.